论文部分内容阅读
近年来,在眼科治疗领域中制成了以高分子聚合物为基质的药物新剂型,统称为膜控释药系统(Membrane Controlled Delivery System)。这种膜控释药系统以药囊及药膜的形式用于眼部,可以恒定或比较恒定地释出药物,维持结膜囊内药物的一定浓度,使药物持续不断地向眼内渗透。因此,具有提高疗效、节省用药、简比治疗操作、减少毒性作用及过敏反应等特点,为眼科治疗开辟了一条新途径。我们于1978年元月以聚乙烯醇为成膜材料制成了毛果云香硷、强力扩瞳剂、后马托品、利福平、可卡因、地卡因、亲水性软接触镜(亲水软镜)和电光性眼炎释药颗粒等八种药膜,并进行了释药定量分析及临床效果观察。仅介绍如下。
In recent years, in the field of ophthalmic treatment made of polymer based matrix drug formulations, collectively referred to as membrane controlled release delivery system (Membrane Controlled Delivery System). The membrane-controlled drug delivery system in the form of sachets and films for the eye, the constant or relatively constant release of drugs to maintain a certain concentration of drug in the conjunctival sac, the drug continued to infiltrate the eye. Therefore, it has the characteristics of improving the curative effect, saving medication, simplifying the treatment operation, reducing the toxic effect and anaphylaxis, and opening up a new way for ophthalmological treatment. We were in January 1978 to polyvinyl alcohol as a membrane material made of hair cloud rhamnoside, strong dilation agent, horsetail, rifampin, cocaine, dexamethasone, hydrophilic soft contact lenses ( Hydrophilic soft mirror) and electro-ophthalmic ophthalmic drug release granules and other eight kinds of films, and the release of quantitative analysis and clinical observation. Only introduced below.